Skip to main content

Paradigm Revises Profit Forecast

NEW YORK, July 11 - Paradigm Genetics announced yesterday that it had revised its earnings projections for the fourth quarter of 2003 from $.05 to $.06 per share profit to between a loss of $.04 per share and a profit of $.01 cent per share. The original guidance was issued in a year-end conference call held in February.

 

Despite its lowering of projections for profitability, Paradigm now expects to have $13 to $15 million in cash and cash equivalents at the end of 2003, as opposed to the $7 to $9 million projected previously. This new figure includes the $2.5 million line of revolving credit that Paradigm gained as part of its $7.5 million debt financing deal with Silicon Valley Bank of Santa Clara, Calif.The financing deal was also announced yesterday, as reported here.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.